Search results
Results from the WOW.Com Content Network
IDEXX Laboratories, Inc. is an American multinational corporation [3] [4] engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
The ACTH test (also called the cosyntropin, tetracosactide, or Synacthen test) is a medical test usually requested and interpreted by endocrinologists to assess the functioning of the adrenal glands' stress response by measuring the adrenal response to adrenocorticotropic hormone (ACTH; corticotropin) or another corticotropic agent such as tetracosactide (cosyntropin, tetracosactrin; Synacthen ...
Adrenocorticotropic hormone is used as a medication and as diagnostic agent in the ACTH stimulation test. [ 1 ] [ 2 ] : 316, 1165 [ 3 ] : 84, 271 The form that is purified from pig pituitary glands is known as corticotropin [ 1 ] [ 2 ] : 316 is a medication and naturally occurring polypeptide tropic hormone produced and secreted by the anterior ...
Idexx This was more of a mixed report, though -- Idexx met Wall Street's consensus bottom-line estimates but fell short on revenues. The stock entered 2024 on a high note but has now given back ...
Low-dose and high-dose variations of the test exist. [4] The test is given at low (usually 1–2 mg) and high (8 mg) doses of dexamethasone, and the levels of cortisol are measured to obtain the results. [5] A low dose of dexamethasone suppresses cortisol in individuals with no pathology in endogenous cortisol production.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
AOL Mail welcomes Verizon customers to our safe and delightful email experience!
[citation needed] A class action lawsuit filed in 2000 charged Idexx and certain officers and directors of Idexx during the relevant time period with violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, by, among other things, issuing to the investing public materially false and misleading statements concerning the ...